Prevalence of antibiotic resistance in clinical isolates of Mycobacterium kansasii: a systematic review and meta-analysis

References

• Stout JE, Koh W-J, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Inter J Infect Dis. 2016;45:123–134. doi: 10.1016/j.ijid.2016.03.006
   PubMed Web of Science ®Google Scholar
• van der Loeff IS, Owens S. Non-tuberculous mycobacterial infection in children. Paediatrics Child Health. 2021;31(3):102–109. doi: 10.1016/j.paed.2020.12.002
   Google Scholar
• Blanc S, Robinson D, Fahrenfeld N. Potential for nontuberculous mycobacteria proliferation in natural and engineered water systems due to climate change: a literature review. City Environ Interact. 2021;11:100070. doi: 10.1016/j.cacint.2021.100070
   Google Scholar
• Yan M, Brode SK, Marras TK. The other nontuberculous mycobacteria: clinical aspects of lung disease caused by less common slowly growing nontuberculous mycobacteria species. Chest. 2022;163(2):281–291. doi: 10.1016/j.chest.2022.09.025
   PubMed Web of Science ®Google Scholar
• Thomson RM, Carter R, Tolson C, et al. Factors associated with the isolation of nontuberculous mycobacteria (NTM) from a large municipal water system in Brisbane, Australia. BMC Microbiol. 2013;13(1):1–8. doi: 10.1186/1471-2180-13-89
   PubMedGoogle Scholar
• Woods GL, Washington JA. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis. 1987;9(2):275–294. doi: 10.1093/clinids/9.2.275
   PubMedGoogle Scholar
• Brown-Elliott BA. Laboratory diagnosis and antimicrobial susceptibility testing of nontuberculous mycobacteria. Nontubercul Mycobac Dis: A Compre App Diagnosis And Manage. 2019 24;57(10):e00834–19.
   Google Scholar
• Woods GL, Brown-Elliott BA, Conville PS, et al. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria. J Clin Microbiol. 2019;57(10). doi: 10.1128/JCM.00834-19
   PubMed Web of Science ®Google Scholar
• Hershko Y, Adler A. Antimicrobial susceptibility distributions of clinical isolates of nontuberculous mycobacteria in Israel. Microbial Drug Resist. 2023;29(7):302–308. doi: 10.1089/mdr.2023.0024
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Woods GL, Kraft CS. Antimycobacterial susceptibility testing of nontuberculous mycobacteria. J Clin Microbiol. 2019;57(10). doi: 10.1128/JCM.00834-19
   Web of Science ®Google Scholar
• Huang H-L, Lu P-L, Lee C-H, et al. Treatment of pulmonary disease caused by Mycobacterium kansasii. J Formosan Med Assoc. 2020;119:S51–S57. doi: 10.1016/j.jfma.2020.05.018
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi: 10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10. doi: 10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–2133. doi: 10.11124/JBISRIR-D-19-00099
   PubMedGoogle Scholar
• Kim Y-G, Lee HY, Kwak N, et al. Determination of clinical characteristics of mycobacterium kansasii-derived species by reanalysis of isolates formerly reported as M. kansasii. Ann Lab Med. 2021;41(5):463–468. doi: 10.3343/alm.2021.41.5.463
   PubMed Web of Science ®Google Scholar
• Gitti Z, Mantadakis E, Maraki S, et al. Clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria from patients in Crete, Greece. Future Microbiol. 2011;6(9):1099–1109. doi: 10.2217/fmb.11.91
   PubMed Web of Science ®Google Scholar
• Lee EH, Chin B, Kim YK, et al. Clinical characteristics of nontuberculous mycobacterial disease in people living with HIV/AIDS in South Korea: a multi-center, retrospective study. PLoS One. 2022;17(11):e0276484. doi: 10.1371/journal.pone.0276484
   PubMed Web of Science ®Google Scholar
• Guna R, Munoz C, Domínguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of mycobacterium kansasii. J Antimicrob Chemother. 2005;55(6):950–953. doi: 10.1093/jac/dki111
   PubMed Web of Science ®Google Scholar
• Hombach M, Somoskövi A, Hömke R, et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXist. Int J Med Microbiol. 2013;303(5):270–276. doi: 10.1016/j.ijmm.2013.04.003
   PubMed Web of Science ®Google Scholar
• Schulthess B, Schäfle D, Kälin N, et al. Drug susceptibility distributions of mycobacterium chimaera and other nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65(5). doi: 10.1128/AAC.02131-20
   Web of Science ®Google Scholar
• Rastogi N, Goh KS, Guillou N, et al. Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs? Zentralblatt für Bakteriologie. 1992;277(4):474–484. doi: 10.1016/S0934-8840(11)80472-X
   PubMedGoogle Scholar
• Alcaide F, Calatayud L, Santín M, et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against mycobacterium kansasii. Antimicrob Agents Chemother. 2004;48(12):4562–4565. doi: 10.1128/AAC.48.12.4562-4565.2004
   PubMed Web of Science ®Google Scholar
• Contreras M, Cheung O, Sanders D, et al. Pulmonary infection with Nontuberculous Mycobacteria1, 2. Am Rev Respir Dis. 1988;137(1):149. doi: 10.1164/ajrccm/137.1.149
   PubMedGoogle Scholar
• Durão V, Silva A, Macedo R, et al. Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines. Pulmonology. 2019;25(3):162–167. doi: 10.1016/j.pulmoe.2018.09.001
   PubMed Web of Science ®Google Scholar
• Liu C-F, Song Y-M, He W-C, et al. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty. 2021;10(1):1–12. doi: 10.1186/s40249-021-00844-1
   PubMed Web of Science ®Google Scholar
• He G, Wu L, Zheng Q, et al. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract. Ann Med. 2022;54(1):2499–2509. doi: 10.1080/07853890.2022.2121984
   Web of Science ®Google Scholar
• da Silva Telles MA, Chimara E, Ferrazoli L, et al. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol. 2005;54(10):975–979. doi: 10.1099/jmm.0.45965-0
   PubMed Web of Science ®Google Scholar
• Heidarieh P, Mirsaeidi M, Hashemzadeh M, et al. In vitro antimicrobial susceptibility of nontuberculous mycobacteria in Iran. Microbial Drug Resist. 2016;22(2):172–178. doi: 10.1089/mdr.2015.0134
   PubMed Web of Science ®Google Scholar
• Goldenberg T, Gayoso R, Mogami R, et al. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016. J Bras Pneumol. 2020;46(6):e20190345–e20190345. doi: 10.36416/1806-3756/e20190345
   PubMed Web of Science ®Google Scholar
• Li Y, Pang Y, Tong X, et al. Mycobacterium kansasii subtype I is associated with clarithromycin resistance in China. Front Microbiol. 2016;7:2097. doi: 10.3389/fmicb.2016.02097
   PubMed Web of Science ®Google Scholar
• Guo Y, Cao Y, Liu H, et al. Clinical and microbiological characteristics of Mycobacterium kansasii pulmonary infections in China. Microbiol Spectr. 2022;10(1):e01475–21. doi: 10.1128/spectrum.01475-21
   PubMed Web of Science ®Google Scholar
• Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother. 2001;45(11):3056–3058. doi: 10.1128/AAC.45.11.3056-3058.2001
   PubMed Web of Science ®Google Scholar
• Huang W-C, Yu M-C, Huang Y-W. Identification and drug susceptibility testing for nontuberculous mycobacteria. J Formosan Med Assoc. 2020;119:S32–S41. doi: 10.1016/j.jfma.2020.05.002
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhao H, Yuan H, et al. Prevalence and antimicrobial susceptibility of non-tuberculous mycobacteria isolated from sputum samples of patients with pulmonary infections in China. Jundishapur J Microbiol. 2021;14(1). doi: 10.5812/jjm.109676
   Web of Science ®Google Scholar
• Akapelwa ML. Molecular characterization of mycobacterium avium clinical isolates from Japan and development of diagnostic tools [dissertation]. 北海道大学; 2022.
   Google Scholar
• Huh HJ, Kim S-Y, Jhun BW, et al. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infect Genet Evol. 2019;72:169–182. doi: 10.1016/j.meegid.2018.10.003
   PubMed Web of Science ®Google Scholar
• Hjelm U, Kaustova J, Kubin M, et al. Susceptibility of mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid. Eur J Clin Microbiol Infect Dis. 1992;11(1):51–54. doi: 10.1007/BF01971272
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of mycobacterium kansasii lung disease: results of a preliminary study. Clinl Infect Dis. 2003;37(9):1178–1182. doi: 10.1086/378742
   PubMed Web of Science ®Google Scholar
• Basille D, Jounieaux V, Andrejak C, editors. Treatment of other nontuberculous mycobacteria. Semin Respir Crit Care Med. 2018 Jun 39(03):377–382.
   Google Scholar